Focused On-demand Library for D-2-hydroxyglutarate dehydrogenase, mitochondrial

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.







Alternative names:


Alternative UPACC:

Q8N465; B4E3L6; E7ENP2; Q6IQ24; Q8N5Q8


D-2-hydroxyglutarate dehydrogenase, mitochondrial, is a pivotal enzyme that catalyzes the conversion of D-2-hydroxyglutarate (D-2-HG) to alpha-ketoglutarate. This process is crucial for the metabolism of specific hydroxyacids, including D-malate and D-lactate, showcasing a preference for D-2-HG and D-MAL. The enzyme's activity is essential for maintaining metabolic balance within the mitochondria.

Therapeutic significance:

D-2-hydroxyglutarate dehydrogenase plays a critical role in D-2-hydroxyglutaric aciduria 1, a rare metabolic disorder marked by developmental delays, epilepsy, and cardiomyopathy. Understanding the enzyme's function could pave the way for innovative treatments targeting the metabolic pathways involved in this disease.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.